AG
AGIO
—
Nasdaq
Pharmaceuticals
Agios Pharmaceuticals, Inc.
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
1,8B USD
P/E
—
EV / Rev
34,0x
Div yield
—
Op margin
-873,9 %
ROE
-40,2 %
Net margin
-764,0 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$32,75
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
AGIOS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for serious diseases, currently generating limited revenue while incurring significant operating losses to fund its research and development pipeline.
Business. AGIOS Pharmaceuticals, Inc. (AGIO) is a pharmaceutical company operating within the Healthcare sector, specifically focused on the development and sale of pharmaceutical products. The company is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. As no specific operating segments or geographic breakdowns are provided, the firm is described at the industry level as a participant in the broader pharmaceuticals market.
Classification98 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY10 analysts
7 buy3 hold0 sell
Avg 12m price target45,14
Analyst recommendations
10 analysts · consensus BuyBuy7
Hold3
Sell0
12-month price target
45,14
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
10 analysts · indicative
Ownership→
T. Rowe Price Investment Management, Inc.
largest disclosed fund holder
Profitability→
-40,2 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to AGIO. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
- Congressional trades
- CongressJosh Gottheimer — Agios Pharmaceuticals, Inc.2024-01-24 · Democrat · NJ · Purchase · $1,001 - $15,000
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
AGIOS Pharmaceuticals, Inc. (AGIO) is a pharmaceutical company operating within the Healthcare sector, specifically focused on the development and sale of pharmaceutical products. The company is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. As no specific operating segments or geographic breakdowns are provided, the firm is described at the industry level as a participant in the broader pharmaceuticals market.
Classification98 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
Industry groupPharmaceuticals
AI synthesis
GENERATEDAGIOS Pharmaceuticals maintains a robust balance sheet characterized by zero debt and substantial liquidity. As of Q2 2026, the company holds $99.6 million in cash and equivalents, alongside significant marketable securities, resulting in a current ratio of 10.22. The debt-to-equity ratio stands at 0.0, indicating no leverage risk. The market capitalization is approximately $1.94 billion, with a price-to-book ratio of 1.89. The company’s total assets amount to $1.11 billion, while total liabilities are minimal at $82.4 million. This strong liquidity position supports ongoing operations without immediate refinancing needs.
The company is not yet profitable, reporting a net loss of $199.8 million and an operating loss of $220.6 million for the period. Return on equity is negative at -40.23%, and return on assets is -37.24%, reflecting the pre-commercial stage of its business model. Revenue for the quarter was $65.5 million, resulting in an EV/Revenue multiple of 34.0. The negative EV/EBITDA of -3.89 underscores the current lack of earnings. These metrics are typical for early-stage biopharma firms investing heavily in R&D before achieving commercial scale.
Key takeaways
- Strong liquidity position with $99.6 million in cash and a current ratio of 10.22, mitigating short-term financial risk.
- Significant operating losses of $220.6 million and negative returns on equity and assets, typical for pre-commercial biopharma.
- Medium dilution risk flagged due to potential future capital raises, despite current zero debt.
- Analyst consensus suggests upside potential with a mean price target of $45.14, reflecting confidence in the pipeline.
- Recent 8-K filing indicates material corporate developments, warranting close monitoring of disclosures.
Bull / Bear case
Generated · model-assistedBULL CASE · 5
Analysts project 37.8% upside to a mean price target of $45.14, reflecting strong buy consensus among ten covering analysts.
The company maintains a pristine balance sheet with zero long-term debt and a debt-to-equity ratio of just 0.0873.
Revenue demonstrated a 16.6% compound annual growth rate from FY2023 to FY2025, indicating expanding top-line momentum.
Agios exhibits best-in-class capital efficiency with a Capex-to-Revenue ratio of 0.0799, outperforming the pharmaceutical cohort median.
Liquidity risk is assessed as low, supported by a robust current ratio of 11.46 as of late 2025.
BEAR CASE · 4
Operating income deteriorated to a loss of $472.1 million in FY2025, widening the operating deficit compared to prior periods.
The company faces medium dilution risk, which could erode shareholder value as it continues to fund significant operating losses.
Free cash flow turned negative at -$377.3 million in FY2025, highlighting persistent cash burn despite revenue growth.
Return on invested capital stands at -46.02%, signaling severe inefficiency in generating returns from deployed capital.
In focus — financials by report
Quarterly
Annual
QUARTERLYFiled 2026-06-30
Q1 2026 · Quarter highlights
Revenue $65.5M; Operating income -$220.6M.
Revenue$65.5M
Operating income-$220.6M
Net income-$199.8M
Free cash flow-$178.2M
EPS—
Operating cash flow-$176.2M
Financials
Income statement
Revenue$65.5M
Gross profit—
Operating income-$220.6M
Net income-$199.8M
Margins
Gross margin—
Operating margin-336.8%
Net margin-305.1%
FCF margin-272.1%
Balance sheet
Total assets$1.11B
Total liabilities$82.4M
Total equity$1.03B
Cash & equivalents$99.6M
Long-term debt—
Cash flow
Operating cash flow-$176.2M
CapEx$2.0M
Free cash flow-$178.2M
SBC$31.5M
P&L flow · revenue → net income
Highlights
- ▍Revenue $65.5M
- ▍Operating income -$220.6M
- ▍Net margin -305.1%
QUARTERLYFiled 2026-03-31
Q4 2025 · Quarter highlights
Revenue $20.7M; Operating income -$110.0M.
Revenue$20.7M
Operating income-$110.0M
Net income-$99.1M
Free cash flow-$119.7M
EPS—
Operating cash flow-$118.9M
Financials
Income statement
Revenue$20.7M
Gross profit—
Operating income-$110.0M
Net income-$99.1M
Margins
Gross margin—
Operating margin-530.3%
Net margin-477.7%
FCF margin-576.9%
Balance sheet
Total assets$1.18B
Total liabilities$75.9M
Total equity$1.11B
Cash & equivalents$113.6M
Long-term debt—
Cash flow
Operating cash flow-$118.9M
CapEx$769.0k
Free cash flow-$119.7M
SBC$15.5M
P&L flow · revenue → net income
Highlights
- ▍Revenue $20.7M
- ▍Operating income -$110.0M
- ▍Net margin -477.7%
QUARTERLYFiled 2026-03-31
Q4 2025 · Quarter highlights
Revenue—
Operating income—
Net income-$99.1M
Free cash flow—
EPS—
Operating cash flow—
Financials
Income statement
Revenue—
Gross profit—
Operating income—
Net income-$99.1M
Balance sheet
Total assets—
Total liabilities—
Total equity$1.11B
Cash & equivalents—
Long-term debt—
ANNUALFiled 2025-12-31
FY 2025 · Full-year highlights
Revenue $54.0M; Operating income -$472.1M.
Revenue$54.0M
Operating income-$472.1M
Net income-$412.8M
Free cash flow-$377.3M
EPS—
Operating cash flow-$373.0M
Financials
Income statement
Revenue$54.0M
Gross profit—
Operating income-$472.1M
Net income-$412.8M
Margins
Gross margin—
Operating margin-873.9%
Net margin-764.0%
FCF margin-698.3%
Balance sheet
Total assets$1.30B
Total liabilities$104.1M
Total equity$1.19B
Cash & equivalents$89.1M
Long-term debt—
Cash flow
Operating cash flow-$373.0M
CapEx$4.3M
Free cash flow-$377.3M
SBC$52.6M
P&L flow · revenue → net income
Highlights
- ▍Revenue $54.0M
- ▍Operating income -$472.1M
- ▍Net margin -764.0%
ANNUALFiled 2024-12-31
FY 2024 · Full-year highlights
Revenue $36.5M; Operating income -$425.7M.
Revenue$36.5M
Operating income-$425.7M
Net income$673.7M
Free cash flow-$391.5M
EPS—
Operating cash flow-$389.8M
Financials
Income statement
Revenue$36.5M
Gross profit—
Operating income-$425.7M
Net income$673.7M
Margins
Gross margin—
Operating margin-1166.5%
Net margin1845.9%
FCF margin-1072.7%
Balance sheet
Total assets$1.66B
Total liabilities$122.2M
Total equity$1.54B
Cash & equivalents$76.2M
Long-term debt—
Cash flow
Operating cash flow-$389.8M
CapEx$1.7M
Free cash flow-$391.5M
SBC$42.8M
P&L flow · revenue → net income
Highlights
- ▍Revenue $36.5M
- ▍Operating income -$425.7M
- ▍Net margin 1845.9%
ANNUALFiled 2024-12-31
FY 2025 · Full-year highlights
Revenue $36.5M; Operating income -$425.7M.
Revenue$36.5M
Operating income-$425.7M
Net income$673.7M
Free cash flow-$391.5M
EPS—
Operating cash flow-$389.8M
Financials
Income statement
Revenue$36.5M
Gross profit—
Operating income-$425.7M
Net income$673.7M
Margins
Gross margin—
Operating margin-1166.5%
Net margin1845.9%
FCF margin-1072.7%
Balance sheet
Total assets$1.66B
Total liabilities$122.2M
Total equity$1.54B
Cash & equivalents$76.2M
Long-term debt—
Cash flow
Operating cash flow-$389.8M
CapEx$1.7M
Free cash flow-$391.5M
SBC$42.8M
P&L flow · revenue → net income
Highlights
- ▍Revenue $36.5M
- ▍Operating income -$425.7M
- ▍Net margin 1845.9%
ANNUALFiled 2023-12-31
FY 2023 · Full-year highlights
Revenue $26.8M; Operating income -$391.5M.
Revenue$26.8M
Operating income-$391.5M
Net income-$352.1M
Free cash flow-$297.1M
EPS—
Operating cash flow-$296.1M
Financials
Income statement
Revenue$26.8M
Gross profit—
Operating income-$391.5M
Net income-$352.1M
Margins
Gross margin—
Operating margin-1459.5%
Net margin-1312.6%
FCF margin-1107.5%
Balance sheet
Total assets$937.1M
Total liabilities$126.1M
Total equity$811.0M
Cash & equivalents$88.2M
Long-term debt—
Cash flow
Operating cash flow-$296.1M
CapEx$999.0k
Free cash flow-$297.1M
SBC$44.8M
P&L flow · revenue → net income
Highlights
- ▍Revenue $26.8M
- ▍Operating income -$391.5M
- ▍Net margin -1312.6%
ANNUALFiled 2023-12-31
FY 2024 · Full-year highlights
Revenue $26.8M; Operating income -$391.5M.
Revenue$26.8M
Operating income-$391.5M
Net income-$352.1M
Free cash flow-$297.1M
EPS—
Operating cash flow-$296.1M
Financials
Income statement
Revenue$26.8M
Gross profit—
Operating income-$391.5M
Net income-$352.1M
Margins
Gross margin—
Operating margin-1459.5%
Net margin-1312.6%
FCF margin-1107.5%
Balance sheet
Total assets$937.1M
Total liabilities$126.1M
Total equity$811.0M
Cash & equivalents$88.2M
Long-term debt—
Cash flow
Operating cash flow-$296.1M
CapEx$999.0k
Free cash flow-$297.1M
SBC$44.8M
P&L flow · revenue → net income
Highlights
- ▍Revenue $26.8M
- ▍Operating income -$391.5M
- ▍Net margin -1312.6%
Valuation FY
Market price
$30,54
Market cap
$1.94B
Enterprise valueⓘ
$1.84B
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
34.0x
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
1.9x
P / Tangible bookⓘ
1.9x
Tangible book
$1.03B
Net cashⓘ
$99.6M
Current ratioⓘ
10.2
Debt / equityⓘ
—
ROAⓘ
-37.2%
ROEⓘ
-40.2%
Cash conversionⓘ
90.0%
CapEx / revenueⓘ
8.0%
SBC / revenueⓘ
97.3%
Dilution ratioⓘ
-0.8%
Revenue by segment
Business relationships
Business relationships9 disclosed relationships · 2 types · extracted from filings & disclosures
Partners1
Alnylam Pharmaceuticals, Inc.ALNY.OPartner95%Source ↗
Subsidiaries8
EX21:2ddf6d67188dEX21:2ddf6d67188dSubsidiarie97%
EX21:3863e7181f7fEX21:3863e7181f7fSubsidiarie97%
EX21:4e3ceb71bdc1EX21:4e3ceb71bdc1Subsidiarie97%
EX21:b5e147f44b3dEX21:b5e147f44b3dSubsidiarie97%
EX21:bbb95653a323EX21:bbb95653a323Subsidiarie97%
EX21:bca3685fea8aEX21:bca3685fea8aSubsidiarie97%
EX21:be37ea82b329EX21:be37ea82b329Subsidiarie97%
EX21:e6edd7f8d10fEX21:e6edd7f8d10fSubsidiarie97%
Supply chain
Vendors → AGIO ↔ Partners → Customers · click any node to drill
1 mention in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 57 %
EPS
Consensus EPS
-6,26
Predicted surprise
+0,02
Beat probability
57 %
Analysts
10
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-07-31 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -6,26 |
| Revenue | —no estimate | —no estimate | 123,1M USD |
| Operating income | —no estimate | —no estimate | -416,4M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution10 analysts
Strong buy3
Buy4
Hold3
Sell0
Strong sell0
12-month price target$45,14 · Median $46,00
Low $32,00High $62,00
Operating income · consensus-416,4M USD
EPS surprise
−13,7 %
reported vs consensus · miss
Revenue surprise
−56,1 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$32,00
Mean$45,14
Median$46,00
High$62,00
Spot$30,54
+47.8 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskMedium
Liquidity riskLow
Filing-based flags
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
Op Margin-873,9 %Bottom quartile
Net Margin-764,0 %Bottom quartile
ROE-40,2 %Bottom quartile
Capex / Rev8,0 %Best in class
D/E0,00Above P75
Cash Conv0,90Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 35 363 sh26 exercises · 24 grants15 insiders
- Director · Restricted stock units → Common stockDisposed 1 447exercise · 2026-07-08
- Chief Medical Officer · Restricted stock units → Common stockDisposed 8 375exercise · 2026-07-01
- Director · Stock options (right to buy) → Common stockAcquired 14 950 @ $34,16grant · 2026-06-18
- Chief Strategy and Operations · Performance share units → Common stockDisposed 3 000exercise · 2026-06-18
- Chief Strategy and Operations · Restricted stock units → Common stockAcquired 3 000grant · 2026-06-18
- Director, Chief Executive Officer · Performance share units → Common stockDisposed 39 000exercise · 2026-06-18
- Director, Chief Executive Officer · Restricted stock units → Common stockAcquired 39 000grant · 2026-06-18
- Chief Legal Officer · Performance share units → Common stockDisposed 3 000exercise · 2026-06-18
- Director · Restricted stock units → Common stockDisposed 2 816exercise · 2026-06-18
- Director · Stock options (right to buy) → Common stockAcquired 14 950 @ $34,16grant · 2026-06-18
- Director · Restricted stock units → Common stockAcquired 2 927grant · 2026-06-18
- Chief Commercial Officer · Restricted stock units → Common stockAcquired 3 000grant · 2026-06-18
- Chief Commercial Officer · Performance share units → Common stockDisposed 3 000exercise · 2026-06-18
- Chief Financial Officer · Restricted stock units → Common stockAcquired 3 000grant · 2026-06-18
- Chief Financial Officer · Performance share units → Common stockDisposed 3 000exercise · 2026-06-18
- Chief Medical Officer · Restricted stock units → Common stockAcquired 3 000grant · 2026-06-18
- Chief Medical Officer · Performance share units → Common stockDisposed 3 000exercise · 2026-06-18
- Chief Legal Officer · Restricted stock units → Common stockAcquired 3 000grant · 2026-06-18
- Director · Restricted stock units → Common stockAcquired 2 927grant · 2026-06-18
- Director · Restricted stock units → Common stockAcquired 2 927grant · 2026-06-18
- Director · Restricted stock units → Common stockDisposed 2 816exercise · 2026-06-18
- Director · Stock options (right to buy) → Common stockAcquired 14 950 @ $34,16grant · 2026-06-18
- Director · Restricted stock units → Common stockAcquired 2 927grant · 2026-06-18
- Director · Restricted stock units → Common stockDisposed 2 816exercise · 2026-06-18
- Director · Stock options (right to buy) → Common stockAcquired 14 950 @ $34,16grant · 2026-06-18
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
Source documents
- AGIOS PHARMACEUTICALS, INC. company facts · 2026-07-31
- AGIOS PHARMACEUTICALS, INC. 10-Q 2026-07-30 · 2026-07-31
- AGIOS PHARMACEUTICALS, INC. 10-Q 2026-04-29 · 2026-07-31
- AGIOS PHARMACEUTICALS, INC. 10-K 2026-02-12 · 2026-07-31
- AGIOS PHARMACEUTICALS, INC. 10-Q 2025-10-30 · 2026-07-31
- 8-K (sec_8k_material) on AGIO · 2026-07-31
- Agios Pharmaceuticals Inc Market data — analyst estimates · 2026-07-31
- Agios Pharmaceuticals Inc Market data — ESG · 2026-07-31
- AGIOS PHARMACEUTICALS, INC. HA canonical relationships · 2026-07-31
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,03 %$0M
- Investment Managers · as of 2026-03-310,01 %$39M
- Investment Managers · as of 2024-06-300,00 %$210M
- Investment Managers · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$22M
- Investment Managers · as of 2026-03-310,00 %$114M
- Investment Managers · as of 2026-03-310,00 %$27M
- Investment Managers · as of 2026-03-310,00 %$50M
- Institutional Investor · as of 2022-09-300,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$16M
- Investment Managers · as of 2026-03-310,00 %$17M
- Investment Managers · as of 2025-12-310,00 %$152M
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$33M
- Investment Managers · as of 2024-12-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$4M
- Funds · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$2M
- Brokerage Firms · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
Net selling0 buys · 10 sellsnet -$1,6M16 insiders · last 365d
- Director · Common stockOther 1 447 · 2026-07-08
- Chief Medical Officer · Common stockOther 8 375 · 2026-07-01
- Chief Medical Officer · Common stockSold 4 007 @ $37,56$151K · 2026-07-01
- Director · Common stockOther 2 816 · 2026-06-18
- Director · Common stockOther 2 816 · 2026-06-18
- Director · Common stockOther 2 816 · 2026-06-18
- Director · Common stockOther 2 816 · 2026-06-18
- Director · Common stockOther 2 816 · 2026-06-18
- Director · Common stockOther 2 816 · 2026-06-18
- Director · Common stockOther 2 816 · 2026-06-18
- Director · Common stockOther 2 816 · 2026-06-18
- Director · Common stockOther 1 976 · 2026-06-13
- Director · Common stockOther 1 976 · 2026-06-13
- Chief Legal Officer · Common stockSold 3 280 @ $34,71$114K · 2026-04-02
- Chief Medical Officer · Common stockOther 8 500 · 2026-04-02
- Chief Medical Officer · Common stockSold 2 940 @ $34,71$102K · 2026-04-02
- Chief Financial Officer · Common stockOther 8 500 · 2026-04-02
- Chief Financial Officer · Common stockSold 3 141 @ $34,71$109K · 2026-04-02
- Chief Commercial Officer · Common stockOther 8 500 · 2026-04-02
- Chief Commercial Officer · Common stockSold 3 262 @ $34,71$113K · 2026-04-02
- Chief Corp Dev & Strategy · Common stockOther 8 100 · 2026-04-02
- Chief Corp Dev & Strategy · Common stockSold 2 959 @ $34,71$103K · 2026-04-02
- Director, Chief Executive Officer · Common stockOther 25 528 · 2026-04-02
- Director, Chief Executive Officer · Common stockSold 12 472 @ $34,71$433K · 2026-04-02
- Director, Chief Executive Officer · Common stockSold 6 596 @ $34,71$229K · 2026-04-02
Short positioning
6.6Mshares short-1.9% vs prior
6.42days to cover
58.3%short of daily vol
34fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
AGIOCanonical
Nasdaq · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskMedium
Liquidity riskLow
Source documents mention dilution or offering risk.
Relationship graph
This companySectorPartnersSubsidiaries
Evidence & claims
From filings & derived data- Capex (annual): USD 4.32MUnknown
- R&D expense (annual): USD 339.54MUnknown
- Total liabilities (annual): USD 104.11MUnknown
- Total assets (annual): USD 1.3BUnknown
- Pre-tax income (annual): USD -413.8MUnknown
- Shareholders' equity (annual): USD 1.19BUnknown
- Cash & equivalents (annual): USD 89.13MUnknown
- Current assets (annual): USD 942.05MUnknown
- Current liabilities (annual): USD 82.21MUnknown
- Shares outstanding (annual): 58.45MUnknown
- EPS (diluted) (annual): USD-PER-SHARES -7Unknown
- Operating cash flow (annual): USD -372.98MUnknown
- Revenue (annual): USD 54.03MUnknown
- Operating income (annual): USD -472.13MUnknown
- Cost of revenue (annual): USD 6.34MUnknown
- Net income (annual): USD -413MUnknown
- EPS (basic) (annual): USD-PER-SHARES -7Unknown
- EPS (basic) (annual): USD-PER-SHARES 12Unknown
- R&D expense (annual): USD 301.29MUnknown
- Pre-tax income (annual): USD 717.97MUnknown
- Current liabilities (annual): USD 81.16MUnknown
- Shareholders' equity (annual): USD 1.54BUnknown
- Shares outstanding (annual): 57.16MUnknown
- EPS (diluted) (annual): USD-PER-SHARES 12Unknown
Showing 24 of 34 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-31 04:36 UTCFILINGMaterial 8-K
2026-07-30 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
2026-07-30EVENTQ2 2026 earnings (expected) estimated date
2026-07-08INSIDERBackstrom Jay T. transacted 1.4k sh — Director
2026-07-08INSIDERBackstrom Jay T. disposed of 1.4k sh Restricted stock units — Director
2026-07-01INSIDERGheuens Sarah transacted 8.4k sh — Chief Medical Officer
2026-07-01INSIDERGheuens Sarah sold 4.0k sh — Chief Medical Officer ~$151k
2026-07-01INSIDERGheuens Sarah disposed of 8.4k sh Restricted stock units — Chief Medical Officer
2026-06-30EARNINGSQuarterly results — Q1 2026 Revenue USD 65.5M · Net USD -199.8M
2026-06-18 00:00 UTCINSIDER50 insider transactions — 2026-06 40 derivative
2026-06-18INSIDERScadden David transacted 2.8k sh — Director
2026-06-18INSIDERBallal Rahul D. transacted 2.8k sh — Director
2026-06-18INSIDERCAPELLO JEFFREY D transacted 2.8k sh — Director
2026-06-18INSIDERFoster-Cheek Kaye I transacted 2.8k sh — Director
2026-06-18INSIDERFOUSE JACQUALYN A transacted 2.8k sh — Director
2026-06-18INSIDERHo Maykin transacted 2.8k sh — Director
2026-06-18INSIDEROwen Adams Catherine transacted 2.8k sh — Director
2026-06-18INSIDERSmith Cynthia transacted 2.8k sh — Director
2026-06-18INSIDERGoff Brian disposed of 39.0k sh Performance share units — Director, Chief Executive Officer
2026-06-18INSIDERGoff Brian acquired 39.0k sh Restricted stock units — Director, Chief Executive Officer
2026-06-18INSIDERBurns James William disposed of 3.0k sh Performance share units — Chief Legal Officer
2026-06-18INSIDERBurns James William acquired 3.0k sh Restricted stock units — Chief Legal Officer
2026-06-18INSIDERGheuens Sarah disposed of 3.0k sh Performance share units — Chief Medical Officer
2026-06-18INSIDERGheuens Sarah acquired 3.0k sh Restricted stock units — Chief Medical Officer
2026-06-18INSIDERJones Cecilia disposed of 3.0k sh Performance share units — Chief Financial Officer
2026-06-18INSIDERJones Cecilia acquired 3.0k sh Restricted stock units — Chief Financial Officer
2026-06-18INSIDERMilanova Tsveta acquired 3.0k sh Restricted stock units — Chief Commercial Officer
2026-06-18INSIDERBackstrom Jay T. acquired 2.9k sh Restricted stock units — Director
2026-06-18INSIDERBackstrom Jay T. acquired 14.9k sh Stock options (right to buy) — Director
2026-06-18INSIDERMilanova Tsveta disposed of 3.0k sh Performance share units — Chief Commercial Officer
2026-06-18INSIDERSmith Cynthia acquired 14.9k sh Stock options (right to buy) — Director
2026-06-18INSIDERViswanadhan Krishnan disposed of 3.0k sh Performance share units — Chief Strategy and Operations
2026-06-18INSIDERViswanadhan Krishnan acquired 3.0k sh Restricted stock units — Chief Strategy and Operations
2026-06-18INSIDERFOUSE JACQUALYN A acquired 2.9k sh Restricted stock units — Director
2026-06-18INSIDERCAPELLO JEFFREY D acquired 14.9k sh Stock options (right to buy) — Director
2026-06-18INSIDERCAPELLO JEFFREY D acquired 2.9k sh Restricted stock units — Director
2026-06-18INSIDERCAPELLO JEFFREY D disposed of 2.8k sh Restricted stock units — Director
2026-06-18INSIDERBallal Rahul D. acquired 2.9k sh Restricted stock units — Director
Showing the 40 most recent of 67 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage